Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06754189

Safety and Performance of UCon Patch Electrode

Led by InnoCon Medical · Updated on 2025-03-27

180

Participants Needed

3

Research Sites

156 weeks

Total Duration

On this page

Sponsors

I

InnoCon Medical

Lead Sponsor

A

Aarhus University Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

UCon is a medical device for treating the symptoms of overactive bladder (OAB) and bowel dysfunction (BD). It electrically stimulates the DGN through the skin to obtain modulated behavior of the bladder/bowel musculature e.g., suppressing undesired bladder/bowel activity to relieve the symptoms of the patient. This pivotal clinical investigation is designed as a stratified-randomized, single-blinded, controlled, confirmatory, prospective, multicenter clinical investigation.

CONDITIONS

Official Title

Safety and Performance of UCon Patch Electrode

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant is 18 years of age or older.
  • Participant is diagnosed with overactive bladder (OAB) or bowel dysfunction (BD).
  • Participant is able to consent, communicate, provide feedback, and understand and follow instructions in Danish during the study, including operating the device at home.
Not Eligible

You will not qualify if you...

  • Genital anatomy does not allow for proper electrode placement or stimulation of the dorsal genital nerve (DGN).
  • Active infection or injured/irritated skin in the genital area where the electrode is placed.
  • Medically unstable due to acute illness or complications unrelated to OAB or BD.
  • Has implanted pacemaker, implantable drug pump, or other active medical devices.
  • Pregnant, nursing, planning pregnancy (confirmed by negative test), or gave birth within the last 12 months; women of childbearing potential must use effective contraception.
  • Enrolled, or planning to enroll, in another conflicting clinical investigation or investigational drug/device trial within the last 12 weeks.
  • Previously participated in a clinical investigation with UCon.
  • Failed other neuromodulation treatments like sacral neuromodulation within 2 years.
  • Has neurological diseases such as multiple sclerosis, stroke, Parkinson's, spinal cord injury, diabetic neuropathy, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyneuropathy.
  • History of cancer in the pelvic region, current cancer treatment, or radiation therapy in the pelvic region.
  • Surgery in pelvic region within last 6 months unless symptoms unrelated to surgery.
  • Addictive behavior involving alcohol, cannabis, opioids, or other intoxicating drugs.
  • For OAB: Planned surgery or diagnostic procedure requiring catheterization or prolonged hospitalization during participation.
  • Male participants with bladder outlet obstruction symptoms due to benign prostatic hyperplasia or prostate cancer.
  • Polyuria or symptoms of polyuria.
  • Current or recurring urinary tract infections (≥3 in last 12 months or ≥2 in last 6 months).
  • Primary diagnosis of stress urinary incontinence or mixed incontinence with stress component likely to confound outcomes.
  • Bladder Pain Syndrome or interstitial cystitis.
  • Botulinum toxin treatment in pelvic region within 9 months or lasting benefit from it.
  • Failed botulinum toxin treatment within last 2 years.
  • Use of antimuscarinics or β3 agonists within 2 weeks.
  • Started estrogen therapy within 3 months or planning to stop therapy during the study.
  • For BD: Planned surgery or diagnostic procedure affecting bowel movements or prolonged hospitalization during participation.
  • Currently treated with antibiotics.
  • History of uncontrolled diarrhea or severe constipation in past 3 months (based on Bristol Stool Form Scale).
  • History of inflammatory bowel disease (Crohn's or ulcerative colitis); irritable bowel syndrome allowed.
  • Major anorectal or bowel surgery history or ongoing conditions requiring surgery unless symptoms unrelated to these conditions.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Aarhus University Hospital

Aarhus, Denmark, 8200

Actively Recruiting

2

Herlev Hospital

Herlev, Denmark, 2730

Actively Recruiting

3

Odense University Hospital

Odense, Denmark, 5000

Actively Recruiting

Loading map...

Research Team

D

Dianna Mærsk Knudsen

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety and Performance of UCon Patch Electrode | DecenTrialz